Angiopoietin-like protein 1 (ANGPTL1) is a potent regulator of angiogenesis. Growing evidence suggests that ANGPTL family proteins not only target endothelial cells but also affect tumor cell behavior. In a screen of 102 patients with lung cancer, we found that ANGPTL1 expression was inversely correlated with invasion, lymph node metastasis, and poor clinical outcomes. ANGPTL1 suppressed the migratory, invasive, and metastatic capabilities of lung and breast cancer cell lines in vitro and reduced metastasis in mice injected with cancer cell lines overexpressing ANGPTL1. Ectopic expression of ANGPTL1 suppressed the epithelial-to-mesenchymal transition (EMT) by reducing the expression of the zinc-finger protein SLUG. A microRNA screen revealed that ANGPTL1 suppressed SLUG by inducing expression of miR-630 in an integrin a 1 b 1 /FAK/ERK/SP1 pathwaydependent manner. These results demonstrate that ANGPTL1 represses lung cancer cell motility by abrogating the expression of the EMT mediator SLUG.
Introduction
Metastasis is the most important contributor to the mortality of patients with cancer (1) . The pathogenesis of cancer metastasis involves increased cell invasion, angiogenesis, cell proliferation, loss of cellular adhesion, survival in the circulation, entry into new tissue, and eventual colonization of distant organs (2) . Recently, a family of proteins structurally similar to the angiopoietins was identified as angiopoietin-like proteins (ANGPTLs), which comprise 7 proteins, ANGPTL1-ANGPTL7 (3). ANGPTLs do not bind to the angiopoietin receptor Tie2 or the elated protein Tie1, which indicates that the functional mechanism of ANGPTL proteins may be different from that of angiopoietins (3) (4) (5) (6) (7) (8) . Several studies show that ANGPTL proteins, similar to angiopoietins, potently regulate angiogenesis. Some ANGPTL proteins also involve multibiological properties, such as cancer cell invasion (4), lipid metabolism (3, 5, 6) , hematopoietic stem cell activity (7) , and inflammation (8) . ANGPTL1 has been reported as an antiangiogenic protein by inhibiting the proliferation, migration, tube formation, and adhesion of endothelial cells as well as tumor growth (9, 10) ; however, little is known about whether ANGPTL1 can influence the malignant properties of cancer cells and the exhaustive mechanisms in cancer progression.
The concept of epithelial-to-mesenchymal transition (EMT) that initially developed in the field of embryology has been extended to explain cancer progression and metastasis (11) . Mesenchymal-to-epithelial transition (MET) is the reverse process of EMT, involving the stabilization of distant metastasis by allowing cancer cells to regain epithelial properties. One of the hallmarks of EMT in cancer is the downregulation of E-cadherin, which is thought to be a repressor of invasion and metastasis. The SNAI, TWIST, and ZEB families have been found to act as oncogenic transcription factors by suppressing E-cadherin expression (12) (13) (14) (15) . MicroRNAs (miRNAs) are small, endogenous, 21-to 23-nucleotide noncoding RNAs belonging to a novel class of gene regulators that play critical roles in physiologic and pathologic processes, including development, viral infection, and cancer (16, 17) . Recent studies demonstrate that miRNAs might affect multiple steps of metastasis, including cancer cell migration, invasion, and intravasation (18) . Actually, the miR-200 family was shown to regulate EMT by inhibiting ZEB1/2. The understanding of miRNA and EMT mechanisms in tumor metastasis is incomplete and remains to be further investigated.
In this study, we reveal what we believe to be the novel mechanism involved in ANGPTL1-mediated suppression of invasion and metastasis of cancer cells. We demonstrate that ANGPTL1 induces MET by downregulation of SLUG through transcriptional regulation of miR-630. Furthermore, we show that ANGPTL1 interacts with integrin α 1 β 1 and represses its downstream signaling to reduce cancer cell migration and invasion. These findings suggest that ANGPTL1 inhibits cancer cell motility and invasiveness through the integrin α 1 β 1 /FAK/ERK/SP1/miR-630/SLUG pathway. addition of blocking antigen and is shown in Supplemental Figure 1A (supplemental material available online with this article; doi:10.1172/JCI64044DS1). ANGPTL1 expression was detectable in normal lung bronchi ( Figure 1B) ; staining was not detected when normal mouse IgG was used ( Figure 1A ). Strong ANGPTL1 staining was observed in the cytoplasm in early-stage lung cancer ( Figure 1C ). In contrast, weak ANGPTL1 staining was observed in advanced-stage lung cancer ( Figure 1D ). ANGPTL1 expression inversely correlated with advanced-stage, higher grade tumor status and higher grade lymph node status (Figure 1 , E-G). Notably, ANGPTL1 expression was higher in a subtype of adenocarcinoma, bronchoalveolar carcinoma, which showed a less invasive phenotype than adenocarcinoma ( Figure 1H ). To study the significance of ANGPTL1 in lymph node metastasis, we collected 12 sets of primary lung tumors with matched lymph node metastatic tumors from the same patient. Interestingly, ANGPTL1 expression was significantly reduced in the lymph node metastatic tumors compared with that in primary lung tumors (n = 12) (Supplemental Figure 1 , B-D). We also found an inverse correlation between ANGPTL1 and lymph node metastasis in patients with breast cancer (n = 52) (Supplemental Figure 2, A-E). Additionally, we analyzed ANGPTL1 mRNA expression in data from a publically available GEO database (19, 20) and found that ANGPTL1 mRNA expression was higher in primary prostate tumors (n = 66) than in lymph node metastatic prostate tumors (n = 15) (Supplemental Figure 2F ). Most importantly, patients with lung cancer with high ANGPTL1 expression had longer overall survival and disease-free survival ( Figure 1, I and J). Taken together, these results indicate that ANGPTL1 inversely correlates with poor prognosis in patients with cancer.
ANGPTL1 inhibits cancer cell migration, invasion, and metastasis. To explore the effects of ANGPTL1 on the invasiveness of cancer cells, we examined the expression of ANGPTL1 in a panel of lung cancer cell lines, CL1-0 and CL1-5, which exhibited increasingly invasive behavior (ref. 21 and Figure 2A ). We also established a similar panel of breast cancer cell lines, MDA- MB-231 and MDA-MB-231/I3 (Figure 2A ). ANGPTL1 mRNA and secreted ANGPTL1 were highly expressed in parental cells (CL1-0 and MDA-MB-231) but were barely detectable in their derivative cells (CL1-5 and MDA-MB-231/I3) ( Figure 2B ). Similar results were also found in other cancer cell lines, including lung and breast cancers (Supplemental Figure 3, A and B) . To further examine the effect of ANGPTL1 on the motility and invasiveness of cancer cells, we transfected ANGPTL1-expressing vectors or control vectors into highly invasive CL1-5, A549, and MDA-MB-231/I3 cells. Overexpression of ANGPTL1 significantly decreased the migratory and invasive capabilities of the lung and breast cancer cells, as assessed by transwell migration and Matrigel invasion assays ( Figure 2C ). In contrast, knockdown of ANGPTL1 in the less invasive CL1-0, MDA-MB-231, H928, and PC14 cells increased their migratory and invasive behaviors ( Figure 2D ). However, our results showed that cells overexpressing ANGPTL1 and cells with ANGPTL1 knockdown exhibited no significant differences in cell proliferation (Supplemental Figure 3C ). Cell motility was also examined using the time-lapse cell tracker assay ( Figure 2E ) and wound healing assay (Supplemental Figure 3D) . The results showed that ANGPTL1 significantly inhibits lung cancer cell migration. Treatment with conditional medium (CM) from HEK293T (293T) cells overexpressing ANGPTL1 (Supplemental Figure  3E ) and ANGPTL1 recombinant protein (rANGPTL1) (Supplemental Figure 3F ) markedly inhibited the migratory and invasive abilities of lung cancer cells. Interestingly, treatment with a specific ANGPTL1 antibody to block the effect of 293T/ ANGPTL1 CM could recover the inhibitory migration and invasion (Supplemental Figure 3E ). These data suggest that the ANGPTL1 plays an important role in the inhibition of lung and breast cancer cell motility and invasiveness. To further investigate the role of ANGPTL1 in an in vivo model, we injected stable transfected cell lines (CL1-5/pcDNA3.1, CL1-5/ANGPTL1, H928/shRNA-Luc, and H928/shRNA-ANGPTL1-1) into the lateral tail vein of SCID mice and detected the lung metastatic nodules. Mice injected with CL1-5/pcDNA3.1 and H928/shR-NA-ANGPTL1-1 cells had more and larger lung metastases than those injected with CL1-5/ANGPTL1 and H928/shRNA-Luc cells, respectively (Figure 2 , F-H, and Supplemental Figure 3G ). Histologic analyses ( Figure 2G ) and RT-PCR (Supplemental Figure 3H ) of lung dissected from each mouse confirmed lung metastases and ANGPTL1 expression, respectively. These results demonstrate that ANGPTL1 is crucial for suppression of lung and breast cancer cell invasion and metastasis.
ANGPTL1 induces MET by downregulating SLUG. We next wanted to identify how ANGPTL1 regulates the migratory and invasive phenotypes of cancer cells. In phase-contrast images, we found that the CL1-5/ANGPTL1 cells appeared round, with a more epithelial morphology than that of CL1-5/pcDNA3.1 cells ( Figure  3A) . In contrast, CL1-0/shRNA-ANGPTL1-1 cells showed a spindle-like, mesenchymal morphology, one of the major characteristics of EMT ( Figure 3A) . Similar results were also found in breast cancer cell lines (Supplemental Figure 4A) . EMT is a critical step in metastasis that involves diverse biological mechanisms (11) . We further investigated the expression of EMT markers and EMT-related transcription factors using Western blot analysis. Our data showed that ANGPTL1 increases the expression of the epithelial marker E-cadherin and represses the expression of mesenchymal markers (N-cadherin, fibronectin, and vimentin) and SLUG protein in lung and breast cancer cell lines ( Figure  3 , B and C; Supplemental Figure 4 , B and C; and Supplemental Figure 6A ). Interestingly, ANGPTL1 affects SLUG protein expression but not SLUG mRNA expression (Supplemental Figure 6 ANGPTL1 represses SLUG expression by inducing expression of miR-630. SLUG degradation may lead to the aberrant SLUG accumulation found in several tumors (22) (23) (24) . Because the levels of SLUG protein were dramatically changed by altered ANGPTL1 expression, we examined the effects of ANGPTL1 on SLUG protein stability. CL1-5/pcDNA3.1 and CL1-5/ANGPTL1 cells were treated with MG132 (26S proteasome inhibitor), and the SLUG protein expression levels were determined. ANGPTL1-mediated reduction of SLUG protein expression was not restored by treatment with MG132 ( Figure 4A ). Furthermore, in the cyclohexi- mide pulse-chase experiment, the half-life of the SLUG protein was not significantly different between CL1-5/pcDNA3.1 and CL1-5/ANGPTL1 cells ( Figure 4B ). Overexpression of ANGPTL1 in a breast cancer cell line, MDA-MB-231/I3, resulted in consistent findings (Supplemental Figure 7, A and B) . These results suggest that SLUG protein stability is not affected by ANGPTL1, indicating that ANGPTL1-modulated MET processes likely occur through posttranscriptional regulation of SLUG. Several studies have shown that miRNAs are involved in the regulation of EMT and cancer progression (25) (26) (27) (28) . To investigate whether ANGPTL1 could regulate miRNA expression, we analyzed global miRNA expression in CL1-5/pcDNA3.1 and CL1-5/ANGPTL1 cells using miRNA microarray analysis. We integrated the miRNA microarray result(s) with 3 online computational algorithms (TargetScan, PicTar, and miRanda) and filtered out 10 candidate miRNAs ( Figure 4C ). We confirmed these candidates using quantitative RT-PCR (qRT-PCR) in CL1-5/ANGPTL1 and CL1-0/shANGPTL1-1 cells and their control cells ( Figure 4D ). Two candidate miRNAs, miR-545 and miR-630, were upregulated by ANGPTL1 in CL1-5 cells and downregulated by shANGPTL1 in CL1-0 cells. To examine whether miR-545 and miR-630 regulate the 3′-UTR of SNAI2 (the SLUG transcripts), we constructed luciferase reporter vectors harboring the wild-type 3′-UTR of the SNAI2 mRNA (WT-3′-UTR) and vectors containing mismatches in the predicted miR-545-and miR-630-binding site (MT-3′-UTR; Figure 4E ) and transfected these vectors into 293T cells at different miRNA-to-reporter ratios. Transfection of the WT-3′-UTR plasmid, but not the MT-3′-UTR plasmid, resulted in suppression of luciferase activity in a dose-dependent manner. This result indicates that miR-545 and miR-630 have a negative effect on SNAI2 3′-UTR expression; miR-630 had more significant repressive effects ( Figure 4E ). We also detected the expression of miR-545 and miR-630 in CL1-5 cells treated with rANGPTL1. The results showed that the expression of miR-545 and miR-630 was significantly induced after rANGPTL1 treatment ( Figure  4F ). Blockage of miR-545 and miR-630 expression using miRNA Figure 10) . We examined whether ANGPTL1 interacted with specific integrins using immunoprecipitation. Analysis of immunoprecipitates from CL1-5 cells treated with V5-tagged ANGPTL1 CM revealed that ANGPTL1 interacts with the integrin α 1 and β 1 ( Figure 5A ). ELISA and surface plasmon resonance results also confirmed the interaction of ANGPTL1 with integrin α 1 β 1 ( Figure 5 , B and C). Previous studies showed that the fibrinogen-like domain (FD) of ANGPTLs is sufficient for integrin binding (31, 32) . We defined the coiledcoil domain (CCD) and FD of ANGPTL1 by Human Protein Reference Database (http://www.hprd.org/) (Supplemental Figure  11A) . We found that the FD of ANGPTL1 is essential for binding to integrin α 1 and β 1 (Supplemental Figure 11B) . To further investigate the integrin signaling associated with the ANGPTL1-inhibited SLUG, we examined the effects of ANGPTL1 on the activity of integrin β 1 using a specific antibody (34) and downstream signal transduction pathways. The expression of activated integrin β 1 was repressed by ANGPTL1 overexpression ( Figure 5D ). For the downstream signaling, our results showed that phosphorylated FAK, ERK, and AKT were repressed by ANGPTL1 ( Figure 5 , E and F). To confirm the role of ERK and AKT signaling pathways in the regulation of SLUG, we transfected vectors expressing constitutively activated MEK1 (to activate ERK signal) and constitutively activated AKT (myr-AKT) into CL1-5/ANGPTL1 cells. We found that cancer cell migration and invasion and SLUG protein levels were restored by MEK1 ( Figure 6B ) but not by myr-AKT ( Figure 6A ). Next, we investigated the correlation between the expression of ANGPTL1 and p-ERK in patients with lung cancer (n = 27). Western blot results showed that expression of ANGPTL1 inversely correlated with p-ERK expression (Supplemental Figure  12, A and B) . Two important collagen receptors, integrin α 1 β 1 and integrin α 2 β 1 , have been shown to correlate with cell invasiveness and metastasis (35) (36) (37) (38) (39) . To evaluate whether integrin α 1 β 1 is involved in ANGPTL1-regulated cell motility and invasiveness and SLUG expression, we first investigated the expression of integrin α 1 β 1 and integrin α 2 β 1 using RT-PCR. We found that integrin α 1 , integrin α 2 , and integrin β 1 expression levels were not altered after overexpression of ANGPTL1 in CL1-5 cells (Supplemental Figure 13, A and B) . Moreover, we introduced specific shRNAs for each integrin (integrin α 1 , integrin α 2 , and integrin β 1 ) and found that knockdown of integrin α 1 and β 1 in CL1-5 cells abolished rANGPTL1-mediated reduction of cancer cell motility and invasiveness and SLUG expression ( Figure 6, C and D) . To further confirm the role of an outside-in signaling pathway in the regulation of ERK and miR-630, we treated CL1-5/integrin α 1 β 1 knockdown cells with rANGPTL1 and found that the levels of phosphorylated ERK and miR-630 were not altered ( Figure 6, E and F) . Therefore, we concluded that ERK and miR-630 are involved in the regulation of SLUG through an ANGPTL1/integrin α 1 β 1 signaling axis.
ANGPTL1 induces miR-630 transcription through repression of the ERK/ SP1 pathway.
To define the relationship between the ERK signaling pathway and miR-630 expression, we introduced MEK1-and myr-AKT-expressing vectors into CL1-5/ANGPTL1 cells. The results revealed that MEK1, but not myr-AKT, represses the expression of miR-630 ( Figure 7A ). Moreover, ANGPTL1-induced expression of pri-miR-630 and pre-miR-630 was also inhibited by MEK1 ( Figure  7B ). These results show that ERK signaling is essential for miR-630 transcription. To investigate the transcriptional regulation of miR-630 by ANGPTL1, promoter reporter assays were performed. Interestingly, miR-630 is located in exon 14 of the ARIH1 gene (ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1); representative regions approximately 1.2-kb upstream of the transcriptional initiation site of the miR-630 were investigated. To further determine which response element participates in the regulation of miR-630 promoter activity in response to ANGPTL1, we developed a series of miR-630 promoter reporter constructs ( Figure  7C , left). We found that the region of the miR-630 promoter from -137 to -92 bp was critical for ANGPTL1-mediated transcriptional regulation of miR-630 ( Figure 7C , right). A database search for known sequences within the miR-630 promoter (-137 to -92 bp) using AliBaba 2.1 indicated the presence of binding sites for SP1, C/EBPα, ENKTF-1, and HBP-1b ( Figure 7D, top) . SP1 and C/EBPα are known to be phosphorylated by various kinases, including MEK1/ERK (40, 41) . We next investigated whether SP1 or C/EBPα associates with the miR-630 promoter through the MEK1/ERK pathway using ChIP assay. We found that SP1, not C/EBPα, interacts with the miR-630 promoter through the MEK1/ERK pathway ( Figure 7D, bottom) . We also confirmed that this response element participates in ANGPTL1-regulated miR-630 promoter activity by the SP1 mutant construct ( Figure 7E ). These results showed that SP1-binding element in the miR-630 promoter region (-137 to -92 bp) is essential for ANGPTL1-induced miR-630 promoter activity ( Figure 7E ). Furthermore, we established CL1-5/pcDNA3.1 and CL1-5/ANGPTL1 cell lines with SP1 and C/EBPα knockdowns. Knockdown of SP1, but not C/EBPα, induced miR-630 expression and repressed SLUG expression ( Figure 7F and Supplemental Figure 14) . These results suggest that ANGPTL1-induced miR-630 transcription is dependent on repression of the ERK/SP1 pathway.
Discussion
ANGPLT1 is reportedly an antiangiogenic protein, suppressing VEGF/bFGF-induced proliferation, migration, tube formation, and adhesion of endothelial cells in vitro (42) . The influence of ANGPLT1 on tumor growth suppression has been shown in fibrosarcoma and mouse melanoma cell lines, in which tumors from cells overexpressing ANGPTL1 are smaller than those from control cells (9, 42) . These results suggest that ANGPTL1 represses tumor-associated angiogenesis. Here, using genetic modulation of ANGPTL1 and rANGPTL1 treatment in cancer cells, we found that ANGPTL1 effectively suppresses the migratory, invasive, and metastatic capabilities of lung and breast cancer cells. Moreover, our results demonstrate the clinical significance of ANGPTL1, as its expression inversely correlates with malignant phenotypes and directly correlates with longer patient survival. Thus, multiple lines of evidence indicate that ANGPTL1 has a suppressive effect on lung and breast tumor cells, suggesting that downregulation of ANGPTL1 is a crucial step in lung and breast cancer progression.
SLUG is overexpressed in numerous cancers and also promotes invasion in lung adenocarcinoma, glioma, ovarian, and pancreatic bilities. In our results, we found that ANGPTL1 induces the MET process through posttranscriptional downregulation of SLUG. Therefore, we suggest that ANGPTL1 may be a potential target for developing new therapies for managing cancer metastasis.
The miR-200 family has been shown to play an important role in tumor progression through the targeting of the E-cadherin transcriptional repressors ZEB1 and ZEB2 (15, (25) (26) (27) . A recent report has shown that miR-124a and miR-203 play critical roles in cancers (43) (44) (45) (46) (47) . Furthermore, SLUG acts as a predictive marker for the clinical outcome of patients with lung adenocarcinoma, breast, ovarian, colon, and gastric cancers (43, (48) (49) (50) . Recent reports have shown that SLUG promotes resistance to EGFR tyrosine kinase inhibitor target therapy (51) and that its expression in lung adenocarcinoma and breast cancer cells is associated with cancer stem cell properties (52-54). Both drug resistance and cancer stem cell features have the tendency to have tumorigenic or metastatic capa- Protein stability assay and Western blot analysis. For protein stability assays, cells were incubated with cycloheximide (10 μg/ml, Sigma-Aldrich) to inhibit further protein synthesis and incubated with MG132 (10 μM, Sigma-Aldrich) to inhibit 26S proteasome; cells were immediately harvested. Proteins in the total cell lysates were separated on 10%-12% SDS-PAGE and electrotransferred to a polyvinylidene difluoride membrane (Millipore). After the blots were blocked in a solution of 10% skimmed milk, 0.1% Tween 20, and PBS, membrane-bound proteins were probed with primary antibodies (primers used are shown in Supplemental Table 1 ; antibodies used are shown in Supplemental Table 2 ) overnight 4°C. The membranes were washed and then incubated with horseradish peroxidaseconjugated secondary antibodies for 45 minutes. Antibody-bound protein bands were detected using enhanced chemiluminescence reagents (Millipore) and photographed with Kodak X-Omat Blue autoradiography film (Perkin Elmer Life Sciences).
Immunoprecipitation. CL1-5 cells were incubated in ANGPTL1 CM at 37°C for 2 hours. Cells were lysed by brief sonication in coimmunoprecipitation buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM CaCl2, 2 mM MnCl2, 1.2% Triton X-100) supplemented with protease inhibitors cocktails (Sigma-Aldrich) as previously described (59) . Lysates were centrifuged for 30 minutes at 14,500 g, and the resulting supernatant was precleared by incubation with immobilized Protein A/G gel (20 μl; Pierce) for 1 hour at 4°C. The precleared supernatant was subjected to overnight immunoprecipitation using the indicated antibodies (Supplemental Table  2 ) or control IgG antibodies at 4°C. The next day, protein complexes were collected by incubation with 35 μl of immobilized Protein A/G gel for 1 hour at 4°C. The collected protein complexes were washed 5 times with coimmunoprecipitation buffer and eluted by boiling in protein sample buffer under reducing conditions, after which proteins were resolved by SDS-PAGE and analyzed by Western blot.
Surface plasmon resonance. Integrin α1β1 recombinant protein was immobilized onto the ProteOn GLC chip by amine coupling, according to the manufacturer's instructions (Bio-Rad). Different concentrations of ANGPTL1 were introduced into the GLC chip at a flow rate of 30 μl/min for 5 minutes with running buffer (1X PBS, pH 7.2). Global fitting of the data to a Langmuir 1:1 model was used to determine the association (ka), dissociation (kd), and affinity constants (KD) using Scrubber2 (BioLogic Software).
Animal studies. All animal experiments were done in accordance with a protocol approved by the National Taiwan University College of Medicine and National Taiwan University College of Public Health Institutional Animal Care and Use Committees. Female SCID mice (6-8 weeks old) were used. For experimental metastasis assays, 1 × 10 6 cells were resuspended in 0.1 ml PBS and injected into the lateral tail vein. Lung metastatic progression or nodules were monitored and quantified either using the noninvasive bioluminescence system (IVIS-Spectrum) or by counting under dissecting microscope. For orthotopic metastasis assays, 5 × 10 5 (CL1-5) cells and 1 × 10 6 (CL1-0) cells were resuspended in a 1:1 mixture of PBS and GFR-Matrigel (BD). This mixture was then injected into the left lateral thorax of each mouse, as previously described (60) . The metastatic nodules in the right lung were quantified using a dissecting microscope.
miRNA microarray and computational analysis. Total RNA from CL1-5/ pcDNA3.1 and CL1-5/ANGPTL1 cells was isolated. The expression of 365 mature human miRNAs in the cells was profiled using real-time PCR (MicroRNA TaqMan Low Density Array Analysis, Applied Biosystems) and was normalized to RNU48. Microarray data have been deposited in the NCBI GEO database, with accession number GSE42481. We used 3 online computational algorithms (TargetScan 5.0-5.2 version, PicTar, and miRanda 2008), which predicted the binding potential of miRNAs to the 3′-UTR region of SNAI2 and filtered out 10 candidate miRNAs.
inhibiting human embryonic stem cells from differentiating into embryoid bodies and preventing invasiveness, respectively, by targeting SLUG (55, 56) . However, our miRNA microarray data indicated that miR-124a and miR-203 were not significantly altered after ANGPTL1 overexpression. The expression of miRNAs often exhibits developmental stage-specific or tissue-specific patterns, and their regulation occurs transcriptionally or posttranscriptionally (16, 17) . Here, we elucidate a mechanism whereby ANGPTL1 represses lung cancer cell motility and invasiveness through downregulation of SLUG by inducing miR-630 transcription.
Numerous studies have shown that ANGPTLs transduce their signals via integrin pathways. ANGPTL3 induces the adhesion and migration of endothelial cells via integrin α v β 3 (29) . ANGPTL4 interacts with integrin β 3 and integrin β 5 to escape anoikis in tumors and control the migration of keratinocytes (30, 33) . Activation of integrin downstream signaling, such as FAK and ERK phosphorylation, strongly correlates with migration and invasion of cancer cells (57, 58) . Our results showed that ANGPTL1 represses the integrin/FAK/ERK pathway and knockdown of a specific collagen-associated integrin, integrin α 1 β 1 , attenuates ANGPTL1-regulated signaling and subsequent cancer cell behaviors. In addition, in our results showed that ANGPTL1 also could reduce cell adhesion to fibronectin and vitronectin. Therefore, ANGPTL1 may interact with other integrins to execute other cell functions. The details of the adhesion inhibition mechanism will be studied in the future.
In summary, we provide clinical evidence that ANGPTL1 expression inversely correlates with advanced-stage lymph node metastasis and positively correlates with survival of patients with cancer. We demonstrate that ANGPTL1 represses lung cancer cell migration and invasion by regulating the integrin α 1 β 1 /FAK/ERK/SP1/ miR-630/SLUG signaling axis.
Methods
Cell culture, plasmids, transfection, and recombinant protein. Lung adenocarcinoma cell lines (CL1-0 and CL1-5) were established at the National Health Research Institutes laboratory and displayed progressively increasing invasiveness (21) . Lung cancer cell lines (CL1-0, CL1-5, PC14, PC9, H928, H1299, and A549) were grown in RPMI-1640 medium supplemented with 10% FBS. 293T cells were grown in DMEM medium supplemented with 10% FBS. The MDA-MB-231/I3 subline was selected from parental MDA-MB-231 cells as CL1-0 and CL1-5. Breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-231/I3) were grown in DMEM/F12 medium supplemented with 10% FBS. All cell lines were grown at 37°C in a humidified 5% CO2 atmosphere. Full-length ANGPTL1, ANGPTL1-CCD, and ANGPTL1-FD plasmids were cloned into the pcDNA3.1/V5-His Topo vector (Invitrogen). pCIneo-SLUG and pLKO_AS.neo/SLUG were a gift from Yang Pan-Chyr (Department of Internal Medicine, National Taiwan University Hospital). The constitutively activated MEK1 plasmid was provided by Ruey-Hwa Chen (Institute of Biological Chemistry, Academia Sinica). The myr-Akt plasmid was provided by Ching-Chow Chen (Department of Pharmacology, National Taiwan University). miRNA constructs expressing miR-545 and miR-630 were designed by our laboratory, and DNA was synthesized by a biotech company (Mission Biotech). In brief, the pre-miRNA was ligated into a BLOCK-iT Pol II miR RNAi expression vector. Transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Established stable cell lines were generated by transfection with Lipofectamine 2000 followed by selection with G418 (500 μg/ml). rANGPTL1 was purchased from Abnova. Integrin α1β1 recombinant protein was purchased from R&D Systems.
